| Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing E Heitzer, P Ulz, J Belic, S Gutschi, F Quehenberger, K Fischereder, ... Genome medicine 5, 1-16, 2013 | 421 | 2013 |
| Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling M Zuckermann, V Hovestadt, CB Knobbe-Thomsen, M Zapatka, ... Nature communications 6 (1), 7391, 2015 | 305 | 2015 |
| Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection P Ulz, S Perakis, Q Zhou, T Moser, J Belic, I Lazzeri, A Wölfler, A Zebisch, ... Nature communications 10 (1), 4666, 2019 | 173 | 2019 |
| Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer P Ulz, J Belic, R Graf, M Auer, I Lafer, K Fischereder, G Webersinke, ... Nature communications 7 (1), 12008, 2016 | 162 | 2016 |
| Advances in circulating tumor DNA analysis S Perakis, M Auer, J Belic, E Heitzer Advances in clinical chemistry 80, 73-153, 2017 | 122 | 2017 |
| Rapid identification of plasma DNA samples with increased ctDNA levels by a modified FAST-SeqS approach J Belic, M Koch, P Ulz, M Auer, T Gerhalter, S Mohan, K Fischereder, ... Clinical chemistry 61 (6), 838-849, 2015 | 117 | 2015 |
| Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide J Belic, R Graf, T Bauernhofer, Y Cherkas, P Ulz, J Waldispuehl‐Geigl, ... International journal of cancer 143 (5), 1236-1248, 2018 | 46 | 2018 |
| Detection of ctDNA from dried blood spots after DNA size selection K Heider, JCM Wan, J Hall, J Belic, S Boyle, I Hudecova, D Gale, ... Clinical Chemistry 66 (5), 697-705, 2020 | 39 | 2020 |
| mFast-SeqS as a monitoring and pre-screening tool for tumor-specific aneuploidy in plasma DNA J Belic, M Koch, P Ulz, M Auer, T Gerhalter, S Mohan, K Fischereder, ... Circulating Nucleic Acids in Serum and Plasma–CNAPS IX, 147-155, 2016 | 25 | 2016 |
| On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer T Moser, J Waldispuehl-Geigl, J Belic, S Weber, Q Zhou, ... NPJ Precision Oncology 4 (1), 30, 2020 | 19 | 2020 |
| A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker … M Unseld, J Belic, K Pierer, Q Zhou, T Moser, R Bauer, G Piringer, ... International journal of cancer 148 (6), 1452-1461, 2021 | 14 | 2021 |
| Shallow whole-genome sequencing from plasma identifies FGFR1 amplified breast cancers and predicts overall survival C Bourrier, JY Pierga, L Xuereb, H Salaun, C Proudhon, MR Speicher, ... Cancers 12 (6), 1481, 2020 | 14 | 2020 |
| Inference of tumor cell-specific transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection of cancer P Ulz, S Perakis, Q Zhou, T Moser, J Belic, I Lazzeri, A Wlfler, A Zebisch, ... bioRxiv, 2019 | 6 | 2019 |
| Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. Nat Commun. 2015; 6: 7391 M Zuckermann, V Hovestadt, CB Knobbe-Thomsen, M Zapatka, ... Nat Biotechnol 31, 822-826, 2013 | 6 | 2013 |
| Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models CM Sauer, K Heider, J Belic, SE Boyle, JA Hall, DL Couturier, A An, ... EMBO Molecular Medicine 14 (8), e15729, 2022 | 5 | 2022 |
| Sensitive detection of ctDNA in early-stage non-small cell lung cancer patients with a personalized sequencing assay K Heider, D Gale, A Ruiz-Valdepenas, G Marsico, G Sharma, M Perry, ... Cancer 31, 34.4, 2020 | 4 | 2020 |
| Detection of residual disease and recurrence in early-stage non-small cell lung cancer (NSCLC) patients using sensitive personalized ctDNA sequencing assays. K Heider, DG Gale, G Marsico, A Ruiz-Valdepeñas, G Sharma, M Perry, ... Journal of Clinical Oncology 38 (15_suppl), e15560-e15560, 2020 | 3 | 2020 |
| Potentials, challenges and limitations of a molecular characterization of circulating tumor DNA for the management of cancer patients P Ulz, A Gerger, J Belic, E Heitzer LaboratoriumsMedizin 40 (5), 323-334, 2016 | 2 | 2016 |
| Analysis of circulating tumor DNA reveals genomic alterations in metastatic prostate cancer patients treated with abiraterone acetate plus prednisone or enzalutamide J Belic, R Graf, T Bauernhofer, Y Cherkas, U Peter, J Waldispuehl-Geigl, ... Cancer Research 78 (13_Supplement), 2959-2959, 2018 | 1 | 2018 |
| Whole-genome sequencing of circulating tumor DNA reveals relevance of focal amplifications for the management of metastatic prostate cancer J Belic, P Ulz, R Graf, M Auer, K Fischereder, G Hoefler, T Bauernhofer, ... European Journal of Cancer 1 (61), S12, 2016 | 1 | 2016 |
